Tolvaptan activates the Nrf2/HO-1 antioxidant pathway through PERK phosphorylation
Tolvaptan, a vasopressin type 2 receptor antagonist initially developed to increase free-water diuresis, has been approved for the treatment of autosomal dominant polycystic kidney disease in multiple countries. Furthermore, tolvaptan has been shown to improve the renal functions in rodent models of...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6592894/ https://www.ncbi.nlm.nih.gov/pubmed/31239473 http://dx.doi.org/10.1038/s41598-019-45539-8 |